When vemlidy patent expires?

What is the status of vemlidy patent expiration?

Vemlidy, also known as tenofovir alafenamide (TAF), is a nucleotide reverse transcriptase inhibitor used to treat chronic hepatitis B infection. The drug is marketed by Gilead Sciences.

According to DrugPatentWatch.com [1], a patent expiration tracker, the vemlidy patent is still active and won't expire until 2027 in the United States. However, patents for various formulations, dosage forms, and delivery systems may have different expiration dates.

Will vemlidy lose patent protection soon?

No, but its patent will expire in 2027. This means that generic versions of vemlidy will likely come to market in 2027 and later, as companies with a generic version will not be able to enter the market while Gilead's patent is still active.

How will the patent expiration impact patients and healthcare providers?

The patent expiration will likely lead to increased competition, potentially reducing prices and improving accessibility of vemlidy. Healthcare providers may also benefit from increased generic treatment options.

What happens after the patent expires?

After the patent expires, other companies can manufacture and market generic versions of vemlidy. This may lead to increased competition, which could reduce prices and improve patient access to the medication.

Sources:

[1] DrugPatentWatch.com (www.drugpatentwatch.com) - Vemlidy Patent Expiration Date.